|Day's Range||65.57 - 66.12|
|52 Week Range||55.06 - 68.12|
|PE Ratio (TTM)||17.09|
|Earnings Date||Jul 27, 2017 - Jul 31, 2017|
|Dividend & Yield||2.56 (3.91%)|
|1y Target Est||72.28|
In 1Q17, Neupogen generated revenues of ~$148 million, a significant drop from the drug’s 1Q16 revenues of ~$213 million.
NORTH CHICAGO, Ill., May 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 38 th Annual Global Healthcare Conference on Tuesday, June 13, 2017. Bill Chase, executive vice ...
AbbVie expects its biggest drug, Humira, to hit peak international sales in 2018 and then face erosion as cheaper biosimilars enter the market.